

KURZPROTOKOLL
16T-MC-AMAH

Öffentlicher Titel	Phase Studie zu Mirikizumab bei moderater oder schwerer Schuppenflechte
Wissenschaftl. Titel	A Multicenter, Long Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to Severe Plaque Psoriasis
Kurztitel	16T-MC-AMAH
Studienart	multizentrisch, prospektiv, Therapiestudie, offen/unverblindet, Pharma-Studie
Studienphase	Phase III
Erkrankung	Haut: Schuppenflechte (Psoriasis)
Einschlusskriterien	<ul style="list-style-type: none">- Participant must have completed the last visit of an eligible study period of originating study- Participant must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential
Ausschlusskriterien	<ul style="list-style-type: none">- Participant must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study- Participant must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab
Alter	18 Jahre und älter
Prüfzentren	Klinik für Dermatologie, Venerologie und Allergologie (Geschlossen) Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Andreas Pinter Tel: 069 6301-83115 Fax: 069 6301-83175 andreas.pinter@unimedizin-ffm.de
Sponsor	Eli Lilly and Company
Registrierung in anderen Studienregistern	EudraCT 2017-003299-30 ClinicalTrials.gov NCT03556202 (primäres Register)